Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Crowley

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Research Involvement and Engagement|May 19, 2021
Preparing accessible and understandable clinical research participant information leaflets and consent forms: a set of guidelines from an expert consensus conferenceEleanor Coleman, Lydia O'Sullivan, Rachel Crowley, et al.
Trials|August 3, 2025
Trial Forge Guidance 5: ethical considerations in randomised Studies Within A Trial (SWATs)Hanne Bruhn, Shaun Treweek, Charles Weijer, et al.
Metabolism: Clinical and Experimental|July 31, 2012
A comparison of osteoprotegerin with adiponectin and high-sensitivity C-reactive protein (hsCRP) as a marker for insulin resistanceEoin P O'Sullivan, David T Ashley, Colin Davenport, et al.
Thrombosis Research|October 12, 2010
Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic statusEoin P O'Sullivan, David T Ashley, Colin Davenport, et al.
Orphanet Journal of Rare Diseases|October 26, 2023
XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)Lothar Seefried, Ali Alzahrani, Pedro Arango Sancho, et al.
RSC Medicinal Chemistry|January 22, 2021
G-Protein biased opioid agonists: 3-hydroxy-<i>N</i>-phenethyl-5-phenylmorphans with three-carbon chain substituents at C9Eugene S Gutman, Eric Bow, Fuying Li, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 15, 2016
Advanced non-alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alström syndromeLaura L Gathercole, Jonathan M Hazlehurst, Matthew J Armstrong, et al.
The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland|April 21, 2026
Total thyroidectomy or hemithyroidectomy for differentiated thyroid carcinoma?Jennifer L McGarry, Alexandra Zaborowski, Nicola McShane, et al.
Calcified Tissue International|June 6, 2019
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled PeriodAnthony A Portale, Thomas O Carpenter, Maria Luisa Brandi, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Research Involvement and Engagement|May 19, 2021
Preparing accessible and understandable clinical research participant information leaflets and consent forms: a set of guidelines from an expert consensus conferenceEleanor Coleman, Lydia O'Sullivan, Rachel Crowley, et al.
Trials|August 3, 2025
Trial Forge Guidance 5: ethical considerations in randomised Studies Within A Trial (SWATs)Hanne Bruhn, Shaun Treweek, Charles Weijer, et al.
Metabolism: Clinical and Experimental|July 31, 2012
A comparison of osteoprotegerin with adiponectin and high-sensitivity C-reactive protein (hsCRP) as a marker for insulin resistanceEoin P O'Sullivan, David T Ashley, Colin Davenport, et al.
Thrombosis Research|October 12, 2010
Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic statusEoin P O'Sullivan, David T Ashley, Colin Davenport, et al.
Orphanet Journal of Rare Diseases|October 26, 2023
XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)Lothar Seefried, Ali Alzahrani, Pedro Arango Sancho, et al.
RSC Medicinal Chemistry|January 22, 2021
G-Protein biased opioid agonists: 3-hydroxy-<i>N</i>-phenethyl-5-phenylmorphans with three-carbon chain substituents at C9Eugene S Gutman, Eric Bow, Fuying Li, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 15, 2016
Advanced non-alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alström syndromeLaura L Gathercole, Jonathan M Hazlehurst, Matthew J Armstrong, et al.
The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland|April 21, 2026
Total thyroidectomy or hemithyroidectomy for differentiated thyroid carcinoma?Jennifer L McGarry, Alexandra Zaborowski, Nicola McShane, et al.
Calcified Tissue International|June 6, 2019
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled PeriodAnthony A Portale, Thomas O Carpenter, Maria Luisa Brandi, et al.
Pageof 2